Health Care Select Sector SPDR

UCB's Bimzelx Beats AbbVie's Skyrizi in Head-to-Head Psoriatic Arthritis Study with Superior Joint Outcomes

Johnson & Johnson Expected to Grow Sales 7% in 2026, Seen as Strong Investment Due to Stable Model and Dividend History

Zacks Raises UnitedHealth's Q1 2027 EPS Estimate to $6.87

Eli Lilly & UNICEF Launch US$50m Partnership Program for Childhood Chronic Diseases

Resona Asset Management Reduces Stake in Intuitive Surgical by 13.1%

ProShare Advisors Increases Gilead Stake by 39.1% in Q4, Total Holdings Reach 2.2 Million Shares

WHO confirms Merck's Ervebo vaccine as candidate for Ebola prevention

Multiple Institutional Investors Disclose Increased Stakes in UnitedHealth Group on May 19, 2026

Lilly Asia Ventures Participates in Accro Bioscience's $50 Million Series C Financing

Institutional Investor Larson Financial Group LLC Reduces Stake in Eli Lilly

Investment firm Gambit Capital Management makes a new $26.54 million investment in Eli Lilly

Wells Fargo Raises UnitedHealth Group's Price Target to $397

Japan Approves Eli Lilly's Zepbound for Obstructive Sleep Apnea

Gilead Sciences Chief Communications Officer Johanna Mercier Sells Nearly 28k Shares for $3.55M

Bank of America Lowers Intuitive Surgical Target Price to $520, Maintains Buy Rating

Eli Lilly Scales Up AI-Driven Drug R&D and Production with Dell Solutions

Merck Plans to Issue $6 Billion in Bonds to Fund Terns Pharmaceutical Acquisition

Judge grants Luigi Mangione's request to suppress evidence in UnitedHealth CEO murder case

UnitedHealth Group will hold its Annual General Meeting on June 2, 2026

Harbour BioMed releases positive preclinical obesity data on its potential rival drug, LET003

Amesite

Meiwu Tech

InMed Pharmaceuticals

Generation Income Properties

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Co-Diagnostics

MetaVia

Phoenix Asia

BAYVIEW ACQUISITION CORPORATION COM USD0.0001 (S/R) 17/11/2028

NextNRG

Pinned News

置顶新闻

ProShare Advisors LLC Buys 623,752 Shares of Gilead Sciences, Inc. $GILD

The latest batch of 13F filings has been released: In Q1, Berkshire Hathaway increased its stake in Google Class A shares by over 200%, propelling it to the position of its seventh-largest holding. The firm completely exited positions held for nearly seven years—including Amazon, as well as Visa, Mastercard, and UnitedHealth—while simultaneously making a return to the airline sector after a six-year hiatus, investing $2.65 billion to establish a new position in Delta Air Lines. Bridgewater Associates, meanwhile, initiated new positions in TSMC and the Gold ETF (GLD) for the first time; it also increased its holdings in Amazon (elevating it to its top holding), Nvidia, Broadcom, and Micron. Conversely, the firm liquidated its stakes in Salesforce and ServiceNow, and trimmed its positions in Mastercard, Adobe, and others. Institutional capital is currently converging on AI computing power and safe-haven assets. How many of the stocks in your portfolio have caught the eye of these investment giants?

The latest batch of 13F filings has been released: In Q1, Berkshire Hathaway increased its stake in Google Class A shares by over 200%, propelling it to the position of its seventh-largest holding. The firm completely exited positions held for nearly seven years—including Amazon, as well as Visa, Mastercard, and UnitedHealth—while simultaneously making a return to the airline sector after a six-year hiatus, investing $2.65 billion to establish a new position in Delta Air Lines. Bridgewater Associates, meanwhile, initiated new positions in TSMC and the Gold ETF (GLD) for the first time; it also increased its holdings in Amazon (elevating it to its top holding), Nvidia, Broadcom, and Micron. Conversely, the firm liquidated its stakes in Salesforce and ServiceNow, and trimmed its positions in Mastercard, Adobe, and others. Institutional capital is currently converging on AI computing power and safe-haven assets. How many of the stocks in your portfolio have caught the eye of these investment giants?

Big funds' 13Fs are out: betting on AI compute and safe havens

GILD

ARKG

LABU

SBIO

IBBQ

ProShare Advisors LLC increased its stake in Gilead Sciences, Inc. by 39.1% in Q4, acquiring 623,752 shares, bringing its total to 2,217,290 shares valued at $272.15 million. Other institutional investors also adjusted their holdings. Gilead's stock opened at $129.67, with a market cap of $160.99 billion. The company reported $2.03 EPS, exceeding estimates, and announced a quarterly dividend of $0.82 per share.

Market Beat

Gilead Sciences

Gilead Sciences, Inc.

Invesco Biotechnology & Genome ETF

Ark Genomic Revolution ETF

VG Health

Direxion S&P Biotech Bull 3X

ALPS Medical Breakthrough

iShares Global Healthcare

iShares Biotechnology ETF

Invesco Nasdaq Biotechnology ETF

VanEck Biotech ETF

iShares US Pharma

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

UCBJY

UCB announced positive results from the phase 3 BE BOLD trial, showing bimekizumab outperformed risankizumab in treating active psoriatic arthritis. At week 16, 49.1% of bimekizumab patients achieved ACR50 compared to 38.4% for risankizumab. Early improvements were noted as early as week 4. No new safety concerns were reported, although mild to moderate candida infections were more common with bimekizumab.

PharmaTimes

UCB S.A.

United Community Banks

UCB reports positive outcomes for bimekizumab in psoriatic arthritis

IBRX

ImmunityBio presented analyses at the AUA 2026 meeting showing that ANKTIVA plus BCG resulted in higher complete response rates and longer-lasting benefits compared to nadofaragene in BCG-unresponsive non-muscle invasive bladder cancer. The combination also demonstrated a cleaner safety profile against TAR-200. However, the data were derived from cross-trial comparisons, which may affect interpretation by investors and clinicians.

PUBT

ImmunityBio

ImmunityBio reports higher complete response rates for ANKTIVA plus BCG in AUA analysis

PILL

The Supreme Court declined to hear appeals from six drugmakers against Medicare's drug price negotiations. This decision is projected to save patients $1.5 billion and Medicare $6 billion in the first year. Ongoing legal challenges in lower courts may lead to future Supreme Court reviews.

Bristol Myers Squibb

Johnson & Johnson

Direxion Pharma & Medical Bull 3X

Supreme Court rejects drugmakers’ bid to halt Medicare price talks

RNXT

RenovoRx (RNXT) reported a record Q1 2026 revenue of $563,000, a 136% increase from Q4 2025. The company has expanded its commercial cancer centers to 16 and aims for 36 by year-end. Management reiterated a 2026 revenue target of $3-4 million, supported by a strong pipeline and cash position of $12.4 million. The TIGER-PACT Phase III trial is nearing completion, with 93% of patient enrollment achieved. Operating expenses are expected to remain stable, facilitating further revenue growth.

Motley Fool

RenovoRx

SPDR S&P Health Equip

iShares US Medical Devices

RenovoRx (RNXT) Q1 2026 Earnings Transcript

BAYN

BAYRY

Bayer AG announced that the U.S. FDA has granted Priority Review for Asundexian, an oral Factor Xla inhibitor aimed at preventing secondary strokes. This follows positive results from the Phase 3 OCEANIC-STROKE trial. The Priority Review designation highlights the urgency for new secondary stroke prevention methods. Stroke is a leading cause of death in the U.S., with 795,000 cases annually. Bayer's stock closed at $11.02, up 1.10%.

nasdaq

Bayer AG

Bayer

Nasdaq

Bayer Aktiengesellschaft

Bayer Granted Priority Review For Asundexian In Secondary Stroke Prevention

STRO

Duality Biotherapeutics has announced a share buyback plan of up to USD 40 million, funded from internal resources, with shares to be held as treasury stock. Chairman and CEO Zhu Zhongyuan will also purchase up to USD 5 million in shares using personal funds. The announcement was made on May 19, 2026.

Sutro Biopharma

DUALITYBIO-B

HKEX

HKEX-R

Hong Kong Exchanges and Clearing (HKEX)

Duality Biotherapeutics plans share buyback of up to US$40 million

TLSA

Tiziana Life Sciences reported positive data from its expanded-access program for intranasal foralumab in 14 patients with non-active secondary progressive multiple sclerosis. The treatment was well tolerated, with no new safety concerns, and patients showed trends toward stabilizing disability and improvements in fatigue. The company supports further development but notes the small dataset limits conclusions.

Tiziana Life Sciences

Tiziana reports positive expanded-access data for intranasal foralumab in non-active SPMS

LTRN

Lantern Pharma has successfully cleared key protocol changes for its Phase 2 HARMONIC trial of LP-300, focusing on a specific EGFR mutation in never-smokers with advanced non-small cell lung cancer. The study will shift to a single-arm design to expedite enrollment and improve data clarity. Treatment duration will be extended, with further clinical updates expected in the second half of 2026.

Lantern Pharma

Lantern Pharma shifts LP-300 Phase 2 HARMONIC trial to single-arm L858R focus

OGEN

Oragenics has initiated Phase IIa dosing of ONP-002 in Australia, with a cash balance of $6.1M and a Letter of Intent for a CNS device. The trial involves 40 patients and focuses on safety and feasibility, with no serious adverse events reported. The company plans to request an FDA Type C meeting in Q2 2026 and aims for a full IND submission by the end of 2026. R&D expenses have increased by 89% to $0.6M, and an annual meeting is scheduled for June 29, 2026.

TradingView

Oragenics

Oragenics advances ONP-002 Phase IIa in Australia, $6.1M cash and LOI for CNS device

VANI

Vivani Medical director Gregg Williams acquired 1,587,301 common shares for $1,999,999.26 at $1.26 per share. His indirect beneficial ownership increased to 34,531,785 shares, while direct holdings stand at 4,799,200 shares.

Vivani Medical

Vivani Medical director Gregg Williams acquires common shares worth $1,999,999.26

Health Care Select Sector SPDR(XLV.US)